A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia
Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study was to determine the safety of aripiprazole administered
long-term in doses ranging from 10 to 30 mg per day as a maintenance therapy in subjects with
chronic or first episode of schizophrenia. Information on the continued efficacy of
aripiprazole was also gathered in this long-term trial (until 31 Dec 2012 or until
aripiprazole was otherwise available through marketed means and/or reimbursed).
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.